SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

PRIME is the native token of the Echelon Prime Foundation, a Web3 ecosystem advancing the next generation of gaming. Echelon creates and distributes tools to encourage innovation in, and promote the growth of, novel gaming models and economies. The first game to adopt and utilize PRIME is Parallel, a sci-fi trading card game.

Echelon Prime

Echelon Prime is trending as traders speculate on a major reversal, fueled by optimism surrounding the broader altcoin market and the platform's role in the growing Web3 gaming economy. The community is actively discussing potential price floors and long-term targets, with many viewing current volume levels as a prime accumulation phase for a projected breakout.

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

NIGHT is currently attracting significant community attention as it prepares for its mainnet launch, with investors debating the balance between the project's institutional-grade privacy goals and concerns regarding its decentralization and ties to Google Cloud. While some traders are bullish on its long-term potential within the Cardano ecosystem, others are actively discussing airdrop unlock schedules, technical support levels, and the project's ongoing regulatory compliance narrative.

Far below the surface, where light no longer reaches and noise collapses into silence, the Sperm Whale endures.  It does not rely on speed or spectacle. It survives through mass, intelligence, and absolute awareness of its surroundings.  This project is shaped by the same principle — strength formed under pressure, movement guided by understanding, and conviction built where others cannot remain.  While the surface reacts, the deep decides.

The Sperm Whale

SPERMWHALE is experiencing intense trading activity as retail participants leverage social media and community sentiment to fuel rapid price fluctuations and coordinate 'leg ups'. While some holders remain highly bullish on the potential for multi-week growth and repeat runs, critics frequently point to the pattern as a classic high-risk pump-and-dump scheme characterized by extreme volatility.

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is trending amid a flurry of investor frustration and allegations of being a scam, largely driven by ongoing technical difficulties, confusion over claiming tokens, and missing or restricted liquidity on exchanges. Community discussion is sharply divided between users who believe the project's long-term potential remains intact and many others warning of a "rug pull" due to persistent delays, lack of verified contract addresses, and inability to access or trade assets.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending as investors gear up for the upcoming presentation of long-term Week 40 clinical data at the AAD conference, which is being closely watched as a pivotal catalyst for the stock. The community is actively discussing Sonelokimab's potential to establish itself as a best-in-class treatment for Hidradenitis Suppurativa, with many pointing to recent analyst upgrades and continued institutional accumulation as signs of significant upside potential despite recent price volatility.

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and personal computers, including smart phones and tablets, and are delivered through physical retail, digital download, online platforms, and cloud streaming services. The company was founded by Ryan A. Brant in 1993 and is headquartered in New York, NY.

Take-Two Interactive Software, Inc.

Take-Two Interactive is currently trending as investors grapple with the company's decision to delay the highly anticipated release of Grand Theft Auto VI, a move that has sparked widespread community debate regarding institutional selling and insider trading allegations. Despite the near-term volatility and frustration over the revised timeline, many long-term shareholders remain bullish, viewing the current price action as a strategic buying opportunity ahead of an eventual massive marketing push and the title's long-term revenue potential.

Iridium Communications, Inc. operates as a commercial provider of communications services offering true global coverage, connecting people, organizations and assets to and from anywhere, in real time. It offers its services to businesses, the U.S. and foreign governments, non-governmental organizations, and consumers via satellite network, which has an architecture of operational satellites with in-orbit spares and related ground infrastructure. Its products include personal communicators, messengers, and trackers, satellite phones, push-to-talk-devices, broadband terminals, midband terminals, external antennas, docking stations, apps, accessories and developer tools & resources. The company was founded in 2000 and is headquartered in McLean, VA.

Iridium Communications Inc

Iridium Communications is experiencing significant community interest and market volatility, fueled by its ongoing expansion into satellite-based time and location (STL) services following its recent acquisition of Satelles. Investors are closely monitoring the stock's valuation and technical support levels ahead of upcoming earnings, with active discussions focused on its defense contracts, share buyback initiatives, and how it differentiates itself from other satellite competitors.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool is facing intense selling pressure following a disappointing quarterly report that included a dividend cut and lowered forward guidance, fueling concerns over demand softness and competitive headwinds. Investors are actively debating whether the stocks current valuation represents a deep-value opportunity or a continued downward spiral as they weigh the companys structural challenges against its historical role as a cyclical leader in the housing sector.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased community chatter as traders track the upcoming Goliath Layer-1 blockchain mainnet launch. While some investors emphasize the network's potential for institutional DeFi and programmable payments, others remain cautious, debating whether recent price action represents genuine accumulation or another cyclical pump-and-dump setup.

Direxion Shares ETF Trust - Direxion Daily S&P 500 Bull 3X ETF

Direxion Daily S&P 500 Bull 3X Shares

The SPXL is seeing heavy volatility as investors debate whether current market conditions represent a buying opportunity or a deeper correction driven by escalating geopolitical tensions and institutional liquidity concerns. Community sentiment remains polarized, with many traders leveraging the S&P 500's movement through algorithmic signals and triple-leveraged ETFs, while others warn of potential downside risks if current support levels break.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q1 Earnings Forecast for CAPR Issued By HC Wainwright

Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Capricor Therapeutics in a...

<ul class="summary-bullets"><li>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on Friday's selloff.</li><li>B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares.</li><li>The Food and Drug Administration has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22.</li></ul>Shares of Capricor Therapeutics (CAPR) fell 9% on Friday after the company reported a wider-than-expected Q4 loss but Wall Street analysts raised their price targets on the stock over hopes for an approval of the company’s lead candidate.On the company’s fourth-quarter (Q4) <a href="https://stocktwits.com/news-articles/markets/equity/capricor-reports-wider-quaterly-loss-than-expected-but-all-eyes-are-on-deramiocel/cZduNXsRIad">earnings</a> call, CEO Linda Marban <a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-best-week-month-ceo-rules-out-conditional-deramiocel-approval/cZdDdk4RIa1">rejected</a> the possibility that the Deramiocel therapy could receive only a conditional regulatory decision. The U.S. Food and Drug Administration is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">Wall Street Take Aways</h2>Roth Capital analyst Boobalan Pachaiyappan recommended buying shares of Capricor Therapeutics on today's selloff. The 8% pullback is a "transient, healthy and short-lived market correction" following the rally post FDA acceptance of Capricor's application of Deramiocel for the treatment of Duchenne muscular dystrophy, the analyst told investors in a research note. Roth would be buying today's "dislocation" and expects the share price to move towards its price target of $41. The firm has a ‘Buy’ rating on Capricor.B. Riley, meanwhile, raised the firm's price target on CAPR to $63 from $50 and kept a ‘Buy’ rating on the shares. The analyst said that its confidence has increased in a potential smooth approval path for Deramiocel ahead of the August 22 decision date, with shares expected to build into the decision as investors digest additional dataset, the analyst told investors in a research note.Piper Sandler raised the firm's price target on CAPR to $58 from $45 and kept an ‘Overweight’ rating on the shares. The firm noted Capricor ended 2025 with cash of $318 million to fund operations through 2027. The FDA has lifted the previously issued Complete Response Letter and resumed the review of the Biologics License Application for Deramiocel with a decision expected by August 22. Optimistically, the label could include the broad Duchenne muscular dystrophy population, not just DMD cardiomyopathy, Piper argues.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock remained within the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained 138% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-will-delay-release-of-cybercab-until-late-2026-owing-to-safety-issues-fund-manager-predicts/cZdDVgaRIO9">Tesla Will Delay The Release Of Cybercab Until Late-2026 Owing To Safety Issues, Fund Manager Predicts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the lCapricor Therapeutics logo is seen displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

CAPR Stock Slumps But Wall Street Reiterates Optimism For Deramiocel Approval

On the company’s fourth-quarter (Q4) earnings call on Thursday, CEO Linda Marban rejected the possibility that the Deramiocel therapy could receive only a conditional approval.

Equity

B. Riley Financial Issues Positive Forecast for Capricor Therapeutics (NASDAQ:CAPR) Stock Price

B. Riley Financial raised their price target on shares of Capricor Therapeutics from $50.00 to $63.00 and gave the stock a "buy" rating in a report on Friday...

Capricor Therapeutics Stock Slides As Q4 Earnings Miss Estimates

Capricor Therapeutics shares are trading lower Friday afternoon after the biotech company reported a wider-than-expected fourth-quarter loss.read more...

Capricor Therapeutics (NASDAQ:CAPR) Shares Down 6.3% - Time to Sell?

Capricor Therapeutics (NASDAQ:CAPR) Trading Down 6.3% - Should You Sell...

Capricor Therapeutics (NASDAQ:CAPR) Given Overweight Rating at Piper Sandler

Piper Sandler reaffirmed an "overweight" rating and issued a $58.00 target price (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday...

Pier Capital LLC Boosts Stock Position in Capricor Therapeutics, Inc. $CAPR

Pier Capital LLC increased its holdings in Capricor Therapeutics, Inc. (NASDAQ:CAPR - Free Report) by 35.0% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund...

<ul class="summary-bullets"><li>CEO Linda Marban dismissed concerns that Deramiocel would receive a conditional approval, citing a trial that met both primary and key secondary endpoints.</li><li>The company is preparing for a potential launch, with its San Diego manufacturing capable of initially treating about 250 patients per year.</li><li>Capricor reported a wider-than-expected Q4 loss of $0.62 per share and no revenue, but ended 2025 with about $318.1 million in cash.</li></ul>Capricor Therapeutics, Inc. (CAPR) CEO Linda Marban has pushed back on regulatory doubts around its Duchenne Muscular Dystrophy (DMD) therapy Deramiocel, saying there is “no way” the drug ends up with only a conditional FDA approval, providing some<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> is heading for its best week since Feb. 20.<h2 class="st-heading-2">CEO Rejects Conditional Approval Risk For Deramiocel</h2>On the company’s fourth-quarter (Q4) earnings call, CEO Linda Marban rejected the possibility that the therapy could receive only a conditional regulatory decision. “No. There’s no way this would be a conditional approval,” Marban said, noting that the trial supporting the application was a randomized, double-blind, placebo-controlled study that met its primary endpoint as well as key secondary endpoints.The comments came after the U.S. Food and Drug Administration (FDA) accepted Capricor’s&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">resubmitted</a> biologics license application for Deramiocel, setting a PDUFA decision date of Aug. 22.&nbsp;Capricor is seeking full approval of Deramiocel for Duchenne muscular dystrophy (DMD) and expects the data to support labeling that reflects benefits in both skeletal muscle and heart disease associated with the condition.<h2 class="st-heading-2">Launch Preparations Underway</h2>The company is also preparing for commercialization if the therapy wins regulatory clearance. Capricor’s San Diego GMP manufacturing facility has already completed its FDA pre-license inspection and is positioned to support an initial commercial launch. The site currently has&nbsp;the capacity to treat about 250 patients per year.Marban said the company plans to begin stockpiling commercial doses once labeling discussions with the FDA are finalized, signaling confidence in the potential approval.Capricor is also expanding manufacturing capacity with additional clean rooms at the same facility, which the company expects could increase production to roughly 2,500 patients per year once fully operational.<h2 class="st-heading-2">Clinical Data Supporting Approval</h2>Deramiocel’s application is supported by results from the Phase 3 Hope-3 trial, which met its primary endpoint measuring upper-limb function and key cardiac endpoints in patients with Duchenne muscular dystrophy. Additional data presented&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">this week</a> showed reduced cardiac fibrosis and improvements in functional measures tied to daily activities.Marban said physician sentiment around the therapy has strengthened following the new data. “Physicians who before were hopeful are now convinced,” she said, adding that the company is receiving increasing inquiries about prescribing and availability.<h2 class="st-heading-2">CAPR Q4 Review</h2>Capricor reported a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capricor-stock-dmd-therapy-phase3-heart-function-results/cZdu4NvRI9m">Q4 loss</a> of $0.62 per share, wider than analysts’ estimate of a $0.55 loss per share. The company reported nil revenue, compared with about $11.1 million a year ago, as milestone payments tied to its partnership with Nippon Shinyaku had already been fully recognized.The company ended 2025 with about $318.1 million in cash, which will fund operations into late 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for CAPR was ‘extremely bullish’ amid over a 700% surge in message volumes over the past month.<figure class="image"><img src="https://news.stocktwits-cdn.com/capr_ss_png_4b733f342d.webp" alt="capr ss.png" width="971" height="145"><figcaption>CAPR sentiment and message volume as of March 13 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/RaymondBabbitt/message/647418188">said</a>, “Congratulations to the Bulls, and to the patients who have been waiting for a miraculous discovery to treat their illness of DMD - Deramiocel, is just around the corner.”<stembedurl>https://stocktwits.com/RaymondBabbitt/message/647418188</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Bentradez/message/647424625">said</a> interest in Deramiocel was strong, noting that participants are expected to join quickly and that others have been reaching out to try to take part, adding that “the demand is there for sure.”<stembedurl>https://stocktwits.com/Bentradez/message/647424625</stembedurl>The stock has surged over 150% over the past year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

CAPR Stock Heads For Best Week In Nearly A Month: CEO Says 'No Way' Deramiocel Gets Only Conditional Approval

The FDA has accepted Capricor’s resubmitted biologics license application, setting an Aug. 22 PDUFA decision date for Deramiocel in DMD. 

<ul><li>The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million.</li><li>Capricor is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22.</li><li>The FDA reversed course on its previous rejection for Deramiocel earlier this week.</li></ul>&nbsp;Shares of Capricor Therapeutics (CAPR) slid down about 2% after-hours on Thursday, after the company reported wider-than-expected quarterly loss, partially offset by optimism for the company’s pipeline.For the fourth quarter, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.capricor.com/investors/news-events/press-releases/detail/340/capricor-therapeutics-reports-fourth-quarter-and-full-year">reported</a> a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024, and more than a Wall Street estimate of a loss of $0.54.The company reported no revenue for the period, and ended 2025 with cash, cash equivalents, and marketable securities of about $318.1 million. The company now believes this to be sufficient to cover anticipated expenses and capital requirements though 2027.<h2 class="st-heading-2">Optimism For Deramiocel Application</h2>The company is now awaiting the U.S. Food and Drug Administration’s decision on the application for Deramiocel by August 22. If approved, the company said that its San Diego GMP manufacturing facility will support a potential commercial launch.“Capricor enters 2026 with important regulatory and clinical momentum as we work toward potential approval of Deramiocel for the treatment of Duchenne muscular dystrophy (DMD),” said Linda Marbán, CEO of Capricor.The FDA is now expected to rule on Capricor's application for Deramiocel in the treatment of Duchenne Muscular Dystrophy by August 22, 2026, after reversing course on its previous rejection. DMD is a genetic disorder characterized by muscle degeneration.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around CAPR stock stayed within ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<a href="https://stocktwits.com/symbol/CAPR">CAPR stock</a> has gained about 156% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/fly-stock-rallies-on-wall-street-spiking-optimism-after-succesful-alpha-launch/cZdujXtRIaP">FLY Stock Rallies On Wall Street’s Spiking Optimism After Successful Alpha Launch</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Capricor Reports Wider Quarterly Loss Than Expected But All Eyes Are On Muscle Disease Therapy

For the fourth quarter, the company reported a net loss of $0.62 per share, compared to loss of $0.16 per share in the corresponding quarter of 2024.

Capricor Therapeutics Q4 Earnings Call Highlights

Capricor Therapeutics (NASDAQ:CAPR) executives used the company's fourth-quarter and full-year 2025 earnings call to outline progress toward a potential U.S. approval of deramiocel for Duchenne...

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

CAPR
Capricor Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CAPR News

CAPRCapricor Therapeutics Inc